NICE will have a 'crucial role' in the value-based pricing of medicines from 2014, the DH has confirmed.
NICE will have a 'crucial role' in the value-based pricing of medicines from 2014, the DH has confirmed.
Its role will include undertaking an assessment of the costs and benefits of different medicines, drawing on its world-leading expertise and it will be responsible for the full value assessment of medicines under the future system.
Under the new scheme, NICE will be given a broader scope to assess a medicine's benefits and costs in a bid to ensure the price the NHS pays for new medicines is linked to their value to patients.
Value-based pricing will replace the Pharmaceutical Price Regulation Scheme (PPRS) in January 2014.